INDIANAPOLIS, Sept. 14, 2016 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in
the analysis of cancer genomics and resistance to targeted
therapies, will join Lilly as senior vice president, Global
Development & Medical Affairs, for Lilly's Oncology business on
January 1, 2017. He will
succeed Richard Gaynor, M.D., who
will retire after a distinguished career at Lilly.
Dr. Garraway is currently associate professor of medicine in the
Department of Medical Oncology at the Dana-Farber Cancer Institute
and Harvard Medical School, an
associate physician at the Brigham and Women's Hospital, an
Institute Member of the Broad Institute of MIT and Harvard, and an
investigator of the Howard Hughes Medical Institute. He will report
to Sue Mahony, Ph.D., Lilly senior
vice president and president of Lilly Oncology. "We are pleased and
honored to have Dr. Garraway join us at Lilly," Mahony said. "He
has made a tremendous impact in his career and is recognized around
the world as a leader in oncology.
"We know he will provide keen insight and expertise—and will
continue to advance Lilly's work in developing innovative new
medicines to truly make life better for people with cancer around
the world."
Mahony praised Dr. Gaynor for his significant contributions to
the discovery and development of cancer medicines. "Richard is
known for scientific rigor and deep expertise in drug development,
coupled with a personal warmth and care for patients that is truly
inspiring," she said. "He is leaving a remarkable legacy at Lilly
through his impact on the pipeline, people and patients."
About Levi Garraway, M.D.,
Ph.D.
A graduate of Harvard Medical
School, Garraway is director of the Joint Center for Cancer
Precision Medicine, which spans Harvard
teaching hospitals: Dana-Farber Cancer Institute, Brigham and
Women's Hospital, Boston Children's Hospital, and the Broad
Institute of MIT and Harvard. He is also co-leader of the Cancer
Genetics Program at the Dana-Farber/Harvard Cancer Center.
In addition to his work at Harvard,
Dr. Garraway is on the boards of major cancer centers, including
Sloan Kettering, MD Anderson and
Ohio State, and he is chairman of
several major National Institutes of Health (NIH) committees. He
also serves on the American Association for Cancer Research (AACR)
board of directors and was elected president of the American
Society of Clinical Investigation--one of the highest honors for
academic clinician scientists.
He is the author of nearly 200 peer-reviewed scientific articles
and has received many awards, including the Paul Marks Prize for
Cancer Research, the Jane Cooke
Wright Award from AACR, the New Innovator Award from the
NIH, and an Outstanding Investigator Award from the National Cancer
Institute.
Dr. Garraway's industry activities also include being a founder
of Foundation Medicine, a leading company in cancer genomics
diagnostics.
About Lilly Oncology
For more than 50
years, Lilly has been dedicated to delivering life-changing
medicines and support to people living with cancer and those who
care for them. Lilly is determined to build on this heritage and
continue making life better for all those affected by cancer around
the world. To learn more about Lilly's commitment to people with
cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and http://newsroom.lilly.com/social-channels.
C-LLY
Refer to: Janice Chavers; chaversjm@lilly.com;
317-612-4974
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/levi-garraway-md-phd-to-become-senior-vice-president-of-global-oncology-at-lilly-succeeding-richard-gaynor-md-who-is-retiring-after-a-distinguished-career-300327830.html
SOURCE Eli Lilly and Company